| Similar Articles |
|---|
 |
The Motley Fool
March 1, 2005
Charly Travers |
From Rags to Riches One biotech's fate reveals the formula for spotting turnaround investments. BioMarin has yet to turn the corner, but that time is quickly approaching.   |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
April 30, 2008
Brian Lawler |
BioMarin's Bodacious Earnings BioMarin raises revenue guidance for all of its marketed drugs, thanks to strong sales so far in 2008. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
February 24, 2005
Charly Travers |
Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value. |
The Motley Fool
October 29, 2009
Brian Orelli |
Small and Volatile, but Not for Long BioMarin is growing. |
The Motley Fool
November 2, 2006
Brian Lawler |
BioMarin's in Good Health This biopharma has a leg up on the competition by getting its finances in order. Even with its small pipeline, BioMarin appears to be running smoothly. Investors, take note. |
The Motley Fool
April 16, 2004
Charly Travers |
Genzyme's Minor Disappointment The latest sales figures for Genzyme's newest drug, Aldurazyme, show that a potential growth-driving drug may be stalling out. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
May 17, 2005
Charly Travers |
BioMarin Bounces Back After a stumble, one biotech firm is returning to the market's good graces. BioMarin stock has shot up 30% in the past two months and is near its 52-week high. |
The Motley Fool
April 1, 2008
Brian Lawler |
BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan. |
The Motley Fool
July 31, 2009
Brian Orelli |
The Little Orphan That Could After a rough start to the year, Rule Breakers pick BioMarin Pharmaceutical is back on track. |
The Motley Fool
May 2, 2007
Brian Lawler |
BioMarin Moves Ahead The drug developer released first-quarter financial results. Even though BioMarin is not yet profitable, its management team has proven capable in all areas of drug development, from the clinical stage to commercialization. Investors, take note. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
May 25, 2007
Brian Lawler |
BioMarin Waits for Another Drug BioMarin files a marketing application for its lead compound in development. Investors, take note. |
Managed Care
June 2004
Thomas Morrow |
Laronidase Opens Door To Treat Other Rare Disorders The release of alpha-L-iduronidase also demonstrates the wave of future treatments for many other mucopolysaccharidosis (MPS) diseases. |
The Motley Fool
February 27, 2007
Brian Lawler |
Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
January 26, 2005
John Bluis |
Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
October 27, 2009
Brian Orelli |
Small Market, Small Acquisition, Still a Good Move BioMarin does everything small. |
The Motley Fool
August 9, 2007
Brian Lawler |
BioMarin Gets Busy BioMarin Pharmaceutical has a busy remainder of 2007 ahead of it, including regulatory decisions, six clinical trials, and the potential for new products to enter the pipeline. |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
The Motley Fool
February 19, 2009
Brian Orelli |
BioMarin Is Off Track Shares of BioMarin Pharmaceutical, a darling of the drug world whose shares more than doubled in 2007, come crashing down because the growth of years past seems to be waning. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
The Motley Fool
August 6, 2008
Brian Lawler |
BioMarin's New Drugs Mostly Hit Their Targets Near-term volatility in a drugmaker's shares can make for long-term opportunities. Such is the current case with BioMarin Pharmaceutical. |
The Motley Fool
February 18, 2005
John Bluis |
Genzyme's Acquisitions Pay Off With some of this biotech's major decisions coming to fruition, shareholders can have more confidence that management can deliver on its promises. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
The Motley Fool
November 8, 2007
Charly Travers |
BioMarin Tips Its Hand BioMarin Pharmaceutical awaits an FDA decision on its drug Kuvan for the treatment of phenylketonuria. The company's recent conference call implies approval is imminent. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
The Motley Fool
January 7, 2009
Brian Orelli |
A Free Call Option on a Drug Orphan-drug specialist BioMarin announces that it has licensed Riquent, La Jolla Pharmaceutical's phase 3 lupus nephritis treatment. |
The Motley Fool
December 13, 2010
Brian Orelli |
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. |
Pharmaceutical Executive
February 1, 2014
Ben Comer |
The Active Patient: Faces Of Change Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease and having access to social media. |
Pharmaceutical Executive
October 1, 2010 |
Optimizing TV Advertising Placements & Results Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives. |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
The Motley Fool
May 3, 2007 |
BioMarin's Big Moves: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
